"New love of cancer prevention" aspirin re-ed to achieve double flowering in the field of liver and bile

At present, aspirin is the recommended medicine for secondary prevention of cardiovascular disease.
But with the further study of aspirin, scientists have found that its role not only in the field of vascular disease, but also in cancer prevention, and can even be described as a new favorite for cancer prevention.
, following the research progress in the field of liver cancer, has performed equally well in bile tube cancer in recent days.
look at these studies together.
Low-dose aspirin significantly reduces the risk of liver cancer and liver disease-related deaths In March, Harvard University's Tracey Simon and others analyzed data on 50,275 cases of chronic viral hepatitis in Sweden and found that low-dose aspirin significantly reduced the risk of liver cancer and liver disease-related deaths.
was published in the New England Journal of Medicine.
Excluding patients who also had AIDS or had liver cancer, the study included 13,276 patients with hepatitis B and 36,999 cases of hepatitis C, with an average age of 42.7 years, 33.8% female, 7955 with coronary heart disease and 12,358 people with at least one cardiovascular risk factor (diabetes, lipid abnormalities, obesity and hypertension).
14,205 of them took aspirin at daily doses of 75 mg or 160 mg, all for at least 90 days.
a 7.9-year follow-up, 1,612 people were diagnosed with liver cancer and 5,017 died from liver-related causes.
data found that the cumulative incidence of liver cancer in 10 years was 4.0 per cent for aspirin-takers and 8.3 per cent for non-aspirin-takers, with significant differences.
excluding other liver cancer risk factors, the risk of liver cancer was significantly reduced by 31% compared to non-aspirin users.
, the cumulative liver-related mortality rate for aspirin-takers over a 10-year period was 11.0 percent, compared with 17.9 percent for non-aspirin-takers.
risk of liver-related death was 27 percent lower for non-aspirin takers.
duration of use is also closely related to liver cancer risk.
patients who took aspirin for only 3 to 12 months, taking aspirin for 3 to 5 years and more was associated with a 34% and 43% lower risk of liver cancer.
those who stopped taking aspirin during follow-up had a 22 percent and 31 percent higher risk of liver cancer and liver-related death than those who continued to take it.
clinical evidence also supports the anti-inflammatory effects of aspirin to help prevent the development of liver disease and hepatocellular carcinoma.
not only reduces the incidence of liver cancer, as well as the field of bile gallbladder cancer, a recently published study showed that aspirin can reduce the incidence of bile tube cancer and prolong the overall survival of patients with bile tube cancer.
two flowerings in the field of liver and bile.
the risk of developing bilial cancer (BTC) with a medium survival of less than 1 year.
recent studies have shown that aspirin has a certain anti-tumor effect by inhibiting inflammatory reactions, cell proliferation, and plateplate aggregation.
the researchers conducted a retrospective study of the relationship between post-diagnosis use of aspirin and BTC survival.
researchers obtained clinical pathology and follow-up data from CPRD, the UK's electronic medical records database, for adult patients diagnosed with BTC (gallbladder, bile duodenal, kettle and overlapping lesions) between 1990 and 2017.
use of aspirin after diagnosis is defined as recording one or more aspirin prescriptions in CPRD on or after BTC diagnosis day.
study adjusted the effects of gender and age on the survival curve.
results showed that out of 2934 BTC patients, gallbladder cancer accounted for 667 cases (23%), bile duodenal cancer 1559 cases (53%), kettle abdominal cancer 224 cases (8%), overlapping lesions 484 cases (16%).
2415 patients (82%) had died, with a medium survival of 5.8 months (2-15 months between the quarters).
256 (9%) patients used aspirin at baseline, and 349 (12%) started using aspirin after diagnosis.
96% of aspirin users (n-2817) were given a dose of 75 mg.
aspirin significantly reduced gallbladder cancer (HR 0.63; 95% CI, 0.48-0.83), bile tube cancer (HR 0.71; 95% CI, 0.60-0.85), kettle abdominal cancer (HR 0.44; 95% CI, 0.26-0.76), overlapping lesions (HR 0.68; 95% CI, 0.50-0.92) risk of death.
survival benefits were more pronounced in patients who had not used aspirin prior to diagnosis.
Another retrospective queue study published in JAMA found a significant reduction in mortality among all patients with bile trater tumors, with the largest decrease in patients with bile tube cancer (HR, 0.71; 95% CI, 0.60-0.85).
, patients without a history of aspirin use benefited more from taking aspirin after diagnosis than those who took aspirin before diagnosis.
patients who took aspirin had a higher survival rate than those who did not take aspirin, at 62% vs. 26%, respectively.
addition to liver and bile, aspirin has accumulated some evidence in the prevention of breast cancer, colorectal cancer and other cancers.
is like a super power, God's medicine is not called in vain! Where is the next city pool that aspirin will take down? We'll see! Reference source: 1. Simon TG, et al., (2020). Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med, DOI: 10.1056/NEJMoa1912035. 2. Simon, T. G., et al., (2018). Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology, 3. A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. 4. Treatment with metformin is associated with long with a survival in patients with hepatocellular carcinoma. 5. Kehm et al. General use of aspirin and other nonsteroidal anti-incy drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research (2019) 21:52,